We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncternal Therapeutics Inc | NASDAQ:ONCT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.23 | 3.35% | 7.09 | 6.86 | 38.50 | 7.09 | 7.08 | 7.09 | 1,244 | 05:00:10 |
```
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) June 28, 2023
Oncternal Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
000-50549 |
|
62-1715807 |
(State or Other Jurisdiction |
|
(Commission File |
|
(IRS Employer Identification No.) |
12230 El Camino Real Suite 230 (858) 434-1113 |
|
|
(Address and zip code; telephone number, including area code, of registrant’s principal executive offices)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
ONCT |
|
The Nasdaq Stock Market, LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
Oncternal Therapeutics, Inc. (“Oncternal”) held its annual meeting of stockholders on June 28, 2023. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.
For |
|
Against |
|
Abstain |
37,810,779 |
|
1,320,205 |
|
1,052,519 |
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
17,291,535 |
|
3,624,846 |
|
3,790,102 |
|
15,477,020 |
1 year |
|
2 years |
|
3 years |
|
Abstain |
|
Broker Non-Votes |
21,709,587 |
|
373,002 |
|
1,697,435 |
|
926,459 |
|
15,477,020 |
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
20,452,152 |
|
4,072,603 |
|
181,728 |
|
15,477,020 |
For |
|
Against |
|
Abstain |
33,026,902 |
|
5,964,149 |
|
1,192,452 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Oncternal Therapeutics, Inc. |
||
|
|
||
Date: June 29, 2023 |
By: |
/s/ Chase C. Leavitt |
|
|
|
Name: Chase C. Leavitt |
|
|
|
Title: General Counsel & Secretary |
2
1 Year Oncternal Therapeutics Chart |
1 Month Oncternal Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions